Reducing renal accumulation of single-chain Fv against melanoma-associated proteoglycan by coadministration of L-lysine

被引:12
作者
Hamilton, S
Odili, J
Wilson, GD
Kupsch, JM [1 ]
机构
[1] Mt Vernon Hosp, RAFT Inst Plast Surg, Northwood HA6 2RN, Middx, England
[2] Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2RN, Middx, England
关键词
biodistribution; kidney; lysine; melanoma; single-chain Fv; tumour targeting;
D O I
10.1097/00008390-200208000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In view of the rising melanoma incidence and the absence of effective treatments for metastatic disease, there is an urgent need for new methods that allow the early detection of melanoma. To this end, in vivo detection by patient imaging with single-chain Fv (scFv) antibody fragments is an attractive diagnostic approach. However, high nonspecific accumulation of scFvs in the kidney reduces image quality in this body area and prevents the use of scFvs for melanoma radioimmunotherapy. We have tested the effect of coadministration of L-lysine with I-125-labelled scFvs against melanoma-associated proteoglycan on kidney accumulation in a nude mouse xenograft model. Coadministration of L-lysine had no significant effect on tumour accumulation of scFvs or blood clearance, but decreased kidney accumulation by factors of 2.25, 2.3, 6.3 and 5.8, respectively, at 1, 3, 6 and 18 h post-injection, and improved tumour to muscle contrast. The reduction in kidney accumulation was maximal at time points that can be extrapolated to patient studies. The time dependence of the effect suggests that further improvements could be achieved with an optimized dosing regimen. When combined with other strategies to reduce kidney accumulation of scFvs, coadministration of L-lysine has the potential to significantly improve tumour to kidney contrast. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 38 条
[1]   Generating improved single-chain Fv molecules for tumor targeting [J].
Adams, GP ;
Schier, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 231 (1-2) :249-260
[2]  
Adams GP, 1998, CANCER RES, V58, P485
[3]  
*AM CANC SOC, 1998, CANC FACTS FIG
[4]   Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library [J].
Begent, RHJ ;
Verhaar, MJ ;
Chester, KA ;
Casey, JL ;
Green, AJ ;
Napier, MP ;
HopeStone, LD ;
Cushen, N ;
Keep, PA ;
Johnson, CJ ;
Hawkins, RE ;
Hilson, AJW ;
Robson, L .
NATURE MEDICINE, 1996, 2 (09) :979-984
[5]  
BEHR TM, 1995, CANCER RES, V55, P3825
[6]  
Behr TM, 1996, J NUCL MED, V37, P829
[7]  
Behr TM, 1998, INT J CANCER, V77, P787, DOI 10.1002/(SICI)1097-0215(19980831)77:5<787::AID-IJC19>3.3.CO
[8]  
2-#
[9]  
Behr TM, 1997, CANCER-AM CANCER SOC, V80, P2591, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2591::AID-CNCR35>3.0.CO
[10]  
2-5